Trials / Completed
CompletedNCT03405363
Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists
Cohort Study of Cardiovascular Events in Patients With Chronic Obstructive Pulmonary Disease Initiating Olodaterol or Other Long-acting beta2-agonists
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 65,406 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 40 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
Examine the risk of cardiovascular events (cardiac arrhythmia or myocardial ischemia) or all-cause mortality in Chronic Obstructive Pulmonary Disease (COPD) patients who are new users of Olodaterol or other LABAs available for the treatment of COPD.
Detailed description
Purpose: Time Perspective:
Conditions
Timeline
- Start date
- 2018-01-31
- Primary completion
- 2020-02-03
- Completion
- 2020-02-03
- First posted
- 2018-01-23
- Last updated
- 2021-04-30
- Results posted
- 2021-04-30
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT03405363. Inclusion in this directory is not an endorsement.